Search Tag: Sepsis Therapy

ICU Management

DSX Therapeutics and R&D Antibodies Announce Issuance of EU Patents for First-in-Class MABST

2015 24 Jun

aSeptiMab® is a Candidate Therapeutic That Targets and Neutralizes Microvesicle-Associated iNOS and Halts the Sepsis CascadeDSX Therapeutics and its close affiliate Research & Diagnostic Antibodies (R&D Ab®) today announce the European Patent Office has published a Decision to grant patent EP1773390B1 “Improved Therapeutic Agent for iNOS Generating... Read more

ICU Management

Study Uncovers Genetic Evidence: Sepsis Caused by Single Bacteria

2014 24 Mar

A recent study undertaken by an international team of academics and published in the academic journal PLOS Pathogens, has investigated the causes that turn localised infections into the life-threatening systematic disease sepsis, and has found genetic evidence pointing at one single bacteria as the cause.This is the first time that such as discovery... Read more

ICU Management

Sepsis Study: Same Survival Rate Regardless of Treatment Method

2014 20 Mar

Comparing three treatment methods shows same survival rateAccording to a five-year clinical study named ProCESS, for Protocolised Care for Early Septic Shock, and published online on March 18, 2014, in the New England Journal of Medicine, the survival rate for patients with septic shock was the same regardless of whether they received treatment based... Read more

ICU Management

ISICEM 2014: CytoSorbents to Sponsor CytoSorb® Research Symposium

2014 14 Mar

CytoSorbents Corporation, a critical care immunotherapy company using blood purification to treat life-threatening illnesses in the intensive care unit, announced that it will sponsor a research symposium entitled:"SIRS and SEPSIS – New Therapy with CytoSorb®" at the 34th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2014)... Read more


Endorsed Companies